Author

B. L. McClellan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. A. Mujeeb· 2 shared A. Comba· 2 shared A. Taher· 2 shared J. Lahann· 2 shared K. Banerjee· 2 shared M. S. Alghamri· 2 shared P. Kadiyala· 2 shared P. R. Lowenstein· 2 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. A. Mujeeb

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic reprogramming of autophagy leads to uncovering a novel therapeutic target for mutant IDH1 astrocytomas

F. J. Nunez, K. Banerjee, A. A. Mujeeb, A. Mauser, C. E. Tronrud, Z. Zhu, S. Raghuram, M. R. Sheth, J. A. Pena Agudelo, J. Zelaya, A. Taher, P. Kadiyala, S. V. Carney, M. B. Garcia-Fabiani, A. Comba, , M. Castro

This study identifies autophagy as a critical survival pathway in mIDH1 gliomas and shows that inhibiting autophagy enhances radiosensitivity and tumor regression in preclinical models.

bioRxiv · Mar 8, 2024 · PreprintCancer Biology

Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy

M. S. Alghamri, K. Banerjee, A. A. Mujeeb, A. Taher, R. Thalla, B. L. McClellan, M. L. Varela, S. M. Stamatovic, G. Martinez-Revollar, A. Andjelkovic-Zochowska, J. V. Gregory, P. Kadiyala, A. Calinescu, J. A. Jimenez, A. A. Apfelbaum, , M. G. Castro

This paper develops synthetic protein nanoparticles delivering a CXCR4 inhibitor to treat glioma by enhancing immunotherapy and reducing tumor progression.

bioRxiv · Aug 27, 2021 · PreprintCell Biology